For some time now there has been much debate about finding a predictive biomarker of response for EGFR monoclonal antibodies used in the treatment of advanced colorectal cancer.  These include cetuximab (Erbitux) and panitumumab (Vectibix).

After all, we know that they tend to work in wild type disease (as shown in the US label below) and that KRAS and NRAS mutations on codon 12 and 13 on exon 2, as well as others on exon 3 and 4 tend to portend resistance to therapy, but beyond that not much is known.

Cetuximab v2

At the European Cancer Conference in Vienna last month I was intrigued to see some new data emerge that may help researchers better understand and predict which people with metastatic colon cancer are more likely to respond in the future.

Subscribers can log in to learn more or you can sign up in the box below.